tetano
Editor, Senior Moderator
Nat Commun
. 2026 Jun 27.
doi: 10.1038/s41467-026-74860-w. Online ahead of print.
Systemic atopy and upper-airway disease define susceptibility to incident asthma after COVID-19 in Korea
You-Jung Choi[SUP] #[/SUP][SUP] 1 2 [/SUP], Young-Chan Kim[SUP] #[/SUP][SUP] 3 4 [/SUP], Sungho Bea[SUP] 5 6 [/SUP], Ju-Young Shin[SUP] 7 [/SUP], Hyesung Lee[SUP] 8 [/SUP]
Affiliations
Incident asthma is an important respiratory sequela after COVID-19, but it is unclear which allergic phenotypes amplify risk. Using a linked nationwide Korean database of 3,987,182 individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection, we compare claims-based incident asthma in those with pre-existing systemic atopy and/or upper-airway disease (allergic rhinitis, chronic rhinosinusitis, atopic dermatitis or food allergy) versus those without after 1:1 propensity score matching. During follow-up to 31 December 2022, participants with pre-existing disease have higher asthma incidence than matched controls (3.55 vs 2.13 per 1,000 person-years), with a hazard ratio of 1.66 (95% confidence interval 1.58-1.75). Asthma risk is elevated for each condition and increases with greater disease burden. These findings show that pre-existing allergic and upper-airway phenotypes stratify post-COVID incident asthma risk on a national scale, supporting targeted surveillance in high-risk subgroups.
. 2026 Jun 27.
doi: 10.1038/s41467-026-74860-w. Online ahead of print.
Systemic atopy and upper-airway disease define susceptibility to incident asthma after COVID-19 in Korea
You-Jung Choi[SUP] #[/SUP][SUP] 1 2 [/SUP], Young-Chan Kim[SUP] #[/SUP][SUP] 3 4 [/SUP], Sungho Bea[SUP] 5 6 [/SUP], Ju-Young Shin[SUP] 7 [/SUP], Hyesung Lee[SUP] 8 [/SUP]
Affiliations
- PMID: 42364998
- DOI: 10.1038/s41467-026-74860-w
Incident asthma is an important respiratory sequela after COVID-19, but it is unclear which allergic phenotypes amplify risk. Using a linked nationwide Korean database of 3,987,182 individuals with confirmed severe acute respiratory syndrome coronavirus 2 infection, we compare claims-based incident asthma in those with pre-existing systemic atopy and/or upper-airway disease (allergic rhinitis, chronic rhinosinusitis, atopic dermatitis or food allergy) versus those without after 1:1 propensity score matching. During follow-up to 31 December 2022, participants with pre-existing disease have higher asthma incidence than matched controls (3.55 vs 2.13 per 1,000 person-years), with a hazard ratio of 1.66 (95% confidence interval 1.58-1.75). Asthma risk is elevated for each condition and increases with greater disease burden. These findings show that pre-existing allergic and upper-airway phenotypes stratify post-COVID incident asthma risk on a national scale, supporting targeted surveillance in high-risk subgroups.